Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer

NIH RePORTER · NIH · T32 · $223,821 · view on reporter.nih.gov ↗

Abstract

Summary This is a new application that proposes a training program for 3 graduate students and 2 postdoctoral fellows in vaccines and immunotherapies against microbial pathogens and cancer. The rationale for this application is to capitalize on the long-term experience of TJU in the area of vaccines, therapeutics and cancer, the need for a such a unique training opportunity in Philadelphia, and the opportunity to develop a “holistic” training experience in both basic and applied aspects of viral and tumor immunity. An important characteristic of the TPVIIDC is that the diversity of research interests of the 21 preceptors affords an opportunity to provide a comprehensive training experience that integrates basic science, vaccine development and therapeutics. Whereas there are other training programs in cancer immunology or vaccines against infectious diseases there is historically little cross-talk between these highly related research areas. We feel strongly that our program will help to provide better training by providing opportunities in different but related areas of immunology of cancer and infectious diseases. While the students and fellows will spend the majority of their time in their host laboratory, ancillary opportunities will enable interaction with a wide range of the participating faculty, facilitated by shared seminars, retreats and course offerings.

Key facts

NIH application ID
10201425
Project number
5T32AI134646-04
Recipient
THOMAS JEFFERSON UNIVERSITY
Principal Investigator
Matthias Johannes Schnell
Activity code
T32
Funding institute
NIH
Fiscal year
2021
Award amount
$223,821
Award type
5
Project period
2018-09-01 → 2023-08-31